Literature DB >> 21156277

New antibody to stop tumor angiogenesis and lymphatic spread by blocking receptor partnering.

Donald M McDonald1.   

Abstract

Tvorogov et al. (2010) describe in this issue of Cancer Cell an antibody that inhibits homodimerization of vascular endothelial growth factor receptor-3 (VEGFR-3) and its heterodimerization with VEGFR-2, but not ligand binding. The work provides mechanistic insights into receptor dimerization and an approach to suppress both angiogenesis and lymphangiogenesis.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Year:  2010        PMID： 21156277      PMCID： PMC3031147          DOI： 10.1016/j.ccr.2010.11.030

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

Review 1.  Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale.

Authors:  Anil Bagri; Hosein Kouros-Mehr; Kevin G Leong; Greg D Plowman
Journal:  Trends Mol Med       Date:  2010-02-26       Impact factor: 11.951

Review 2.  Lymphangiogenesis: Molecular mechanisms and future promise.

Authors:  Tuomas Tammela; Kari Alitalo
Journal:  Cell       Date:  2010-02-19       Impact factor: 41.582

3.  Structural determinants of growth factor binding and specificity by VEGF receptor 2.

Authors:  Veli-Matti Leppänen; Andrea E Prota; Michael Jeltsch; Andrey Anisimov; Nisse Kalkkinen; Tomas Strandin; Hilkka Lankinen; Adrian Goldman; Kurt Ballmer-Hofer; Kari Alitalo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-09       Impact factor: 11.205

4.  Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling.

Authors:  Jamie B Spangler; Jason R Neil; Sivan Abramovitch; Yosef Yarden; Forest M White; Douglas A Lauffenburger; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-07       Impact factor: 11.205

5.  Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization.

Authors:  Denis Tvorogov; Andrey Anisimov; Wei Zheng; Veli-Matti Leppänen; Tuomas Tammela; Simonas Laurinavicius; Wolfgang Holnthoner; Hanna Heloterä; Tanja Holopainen; Michael Jeltsch; Nisse Kalkkinen; Hilkka Lankinen; Päivi M Ojala; Kari Alitalo
Journal:  Cancer Cell       Date:  2010-12-02       Impact factor: 31.743

Review 6.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

7.  Structure of a VEGF-VEGF receptor complex determined by electron microscopy.

Authors:  Claudia Ruch; Georgios Skiniotis; Michel O Steinmetz; Thomas Walz; Kurt Ballmer-Hofer
Journal:  Nat Struct Mol Biol       Date:  2007-02-11       Impact factor: 15.369

8.  Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.

Authors:  Tuomas Tammela; Georgia Zarkada; Elisabet Wallgard; Aino Murtomäki; Steven Suchting; Maria Wirzenius; Marika Waltari; Mats Hellström; Tibor Schomber; Reetta Peltonen; Catarina Freitas; Antonio Duarte; Helena Isoniemi; Pirjo Laakkonen; Gerhard Christofori; Seppo Ylä-Herttuala; Masabumi Shibuya; Bronislaw Pytowski; Anne Eichmann; Christer Betsholtz; Kari Alitalo
Journal:  Nature       Date:  2008-06-25       Impact factor: 49.962

9.  Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization.

Authors:  Juliana Bentes Hughes; Christian Berger; Marianne Skeie Rødland; Max Hasmann; Espen Stang; Inger Helene Madshus
Journal:  Mol Cancer Ther       Date:  2009-07-07       Impact factor: 6.261

10.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.